File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Therapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo
Title | Therapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo |
---|---|
Authors | |
Issue Date | 2017 |
Citation | The 1st International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity, 2017 How to Cite? |
Abstract | Lung cancer is the top cancer killer which can be divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma. Eighty-five percent of lung cancer cases are NSCLC and adenocarcinoma is the major sub-type. Mesothelioma is a scarce malignant tumour that grows on the mesothelial surface of coelomic cavities which is a difficult-to-treat global disease. The clinically available treatment options include systemic chemotherapy, radiotherapy, targeted therapy and immunotherapy. Nevertheless, alternative therapeutic agents are urgently needed. Arginine is a semi-essential amino acid in selected tumors, but can be replenished intracellularly in normal cells. BCT-100 (arginase) displays anti-cancer activity by depleting arginine to ornithine. BCT-100 has shown anti-tumor effects in hepatocellular carcinoma (HCC), acute myeloid leukemia and melanoma in vitro and in vivo as well as HCC in a phase I/II clinical trial. In this talk, we will present the anti-cancer activity of BCT-100 in mesothelioma as well as combination effect of BCT-100 and alpha-difluoromethylornithine in lung adenocarcinoma using cell line and xenograft models. |
Persistent Identifier | http://hdl.handle.net/10722/247890 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, SK | - |
dc.contributor.author | Ho, JCM | - |
dc.date.accessioned | 2017-10-18T08:34:19Z | - |
dc.date.available | 2017-10-18T08:34:19Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | The 1st International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity, 2017 | - |
dc.identifier.uri | http://hdl.handle.net/10722/247890 | - |
dc.description.abstract | Lung cancer is the top cancer killer which can be divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma. Eighty-five percent of lung cancer cases are NSCLC and adenocarcinoma is the major sub-type. Mesothelioma is a scarce malignant tumour that grows on the mesothelial surface of coelomic cavities which is a difficult-to-treat global disease. The clinically available treatment options include systemic chemotherapy, radiotherapy, targeted therapy and immunotherapy. Nevertheless, alternative therapeutic agents are urgently needed. Arginine is a semi-essential amino acid in selected tumors, but can be replenished intracellularly in normal cells. BCT-100 (arginase) displays anti-cancer activity by depleting arginine to ornithine. BCT-100 has shown anti-tumor effects in hepatocellular carcinoma (HCC), acute myeloid leukemia and melanoma in vitro and in vivo as well as HCC in a phase I/II clinical trial. In this talk, we will present the anti-cancer activity of BCT-100 in mesothelioma as well as combination effect of BCT-100 and alpha-difluoromethylornithine in lung adenocarcinoma using cell line and xenograft models. | - |
dc.language | eng | - |
dc.relation.ispartof | International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity | - |
dc.title | Therapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Lam, SK: sklam77@hku.hk | - |
dc.identifier.email | Ho, JCM: jhocm@hku.hk | - |
dc.identifier.authority | Ho, JCM=rp00258 | - |
dc.identifier.hkuros | 282349 | - |